Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review

Jeffrey N Katz, Kaetlyn R Arant, Richard F Loeser, Jeffrey N Katz, Kaetlyn R Arant, Richard F Loeser

Abstract

Importance: Osteoarthritis (OA) is the most common joint disease, affecting an estimated more than 240 million people worldwide, including an estimated more than 32 million in the US. Osteoarthritis is the most frequent reason for activity limitation in adults. This Review focuses on hip and knee OA.

Observations: Osteoarthritis can involve almost any joint but typically affects the hands, knees, hips, and feet. It is characterized by pathologic changes in cartilage, bone, synovium, ligament, muscle, and periarticular fat, leading to joint dysfunction, pain, stiffness, functional limitation, and loss of valued activities, such as walking for exercise and dancing. Risk factors include age (33% of individuals older than 75 years have symptomatic and radiographic knee OA), female sex, obesity, genetics, and major joint injury. Persons with OA have more comorbidities and are more sedentary than those without OA. The reduced physical activity leads to a 20% higher age-adjusted mortality. Several physical examination findings are useful diagnostically, including bony enlargement in knee OA and pain elicited with internal hip rotation in hip OA. Radiographic indicators include marginal osteophytes and joint space narrowing. The cornerstones of OA management include exercises, weight loss if appropriate, and education-complemented by topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs) in those without contraindications. Intra-articular steroid injections provide short-term pain relief and duloxetine has demonstrated efficacy. Opiates should be avoided. Clinical trials have shown promising results for compounds that arrest structural progression (eg, cathepsin K inhibitors, Wnt inhibitors, anabolic growth factors) or reduce OA pain (eg, nerve growth factor inhibitors). Persons with advanced symptoms and structural damage are candidates for total joint replacement. Racial and ethnic disparities persist in the use and outcomes of joint replacement.

Conclusions and relevance: Hip and knee OA are highly prevalent and disabling. Education, exercise and weight loss are cornerstones of management, complemented by NSAIDs (for patients who are candidates), corticosteroid injections, and several adjunctive medications. For persons with advanced symptoms and structural damage, total joint replacement effectively relieves pain.

Figures

Figure 1A:
Figure 1A:
Bilateral varus deformity with medial joint space narrowing (nearly bone on bone) and osteophyte formation. Thin arrows show joint space narrowing and thick arrows medial marginal osteophytes.
Figure 1B:
Figure 1B:
MRI (proton density, fat saturated) of right knee of 63 year old female. Coronal view on left and saggital view on right. Bone marrow lesions are identified with thin, solid white arrows on the coronal view; meniscal damage and cartilage damage are identified with dashed arrow on saggital view and retropatellar effusion as solid arrow on saggital view.
Figure 2.
Figure 2.
Molecular Mediators of Osteoarthritis. A number of pro-inflammatory factors and anabolic factors are present in joint tissues and in the synovial fluid. Pro-inflammatory mediators contribute to joint tissue destruction in large part by stimulating production of matrix degrading enzymes, including the matrix metalloproteinases, but also through inhibition of matrix synthesis. The anabolic factors stimulate matrix production and, in some cases, also inhibit the catabolic signaling stimulated by pro-inflammatory mediators. Some factors including TGFβ and bFGF are capable of initiating either catabolic or anabolic activity depending on cell type and specific receptors expressed. TGFβ and BMP-2 can also stimulate osteophyte formation. The overall activity in the OA joint is tipped in favor of the pro-inflammatory side. (IL, interleukin; LIF, leukemia inhibitory factor; MCP, monocyte chemoattractant protein, MIF, macrophage migration inhibitory factor; MIG, monokine Induced By Interferon-Gamma; bFGF, basic fibroblast growth factor; TGF, transforming growth factor; IGF, insulin-like growth factor, BMP, bone morphogenetic protein; CDMP; cartilage-derived morphogenetic protein.)
Figure 3.
Figure 3.
Joint Tissue Involvement in Osteoarthritis. OA can involve all joint structures at some point in the disease process. Although articular cartilage degradation and loss is a central feature, changes in the neighboring bone accompany the cartilage damage. These include subchondral bone remodeling resulting in increased thickness, osteophytes, bone marrow lesions and vascular invasion into the overlying cartilage. Inflammatory cells, primarily macrophages, are present in the synovium and can also be noted in peri-articular fat. Meniscal and ligament damage is often found as well. All of these tissues are capable of producing a host of pro-inflammatory factors and matrix degrading enzymes and thus contribute to the progressive remodeling and destruction of the joint.

References

    1. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage. 2015;23(8):1233–1241.
    1. Hawker G Osteoarthritis: a serious disease Osteoarthris Research Society International 2016. .
    1. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2015;386(9995):743–800.
    1. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1987;30(8):914–918.
    1. Jordan JM, Helmick CG, Renner JB, et al. Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. The Journal of Rheumatology. 2007;34(1):172.
    1. Haugen IK, Englund M, Aliabadi P, et al. Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis. 2011;70(9):1581–1586.
    1. Jordan JM, Helmick CG, Renner JB, et al. Prevalence of hip symptoms and radiographic and symptomatic hip osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. The Journal of rheumatology. 2009;36(4):809–815.
    1. Losina E, Weinstein AM, Reichmann WM, et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res (Hoboken). 2013;65(5):703–711.
    1. Brown TD, Johnston RC, Saltzman CL, Marsh JL, Buckwalter JA. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. Journal of orthopaedic trauma. 2006;20(10):739–744.
    1. Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage. 2005;13(9):769–781.
    1. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015. MMWR Morbidity and mortality weekly report. 2017;66(9):246–253.
    1. CPI for All Urban Consumers: All items in U.S. city average, all urban consumers, not seasonally adjusted 2019. . Accessed 1 April 2020.
    1. Losina E, Paltiel AD, Weinstein AM, et al. Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty. Arthritis care & research. 2015;67(2):203–215.
    1. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589.
    1. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum. 2012;64:1697–1707.
    1. Brouwer GM, van Tol AW, Bergink AP, et al. Association between valgus and varus alignment and the development and progression of radiographic osteoarthritis of the knee. Arthritis Rheum. 2007;56(4):1204–1211.
    1. Sharma L, Song J, Felson DT, Cahue S, Shamiyeh E, Dunlop DD. The role of knee alignment in disease progression and functional decline in knee osteoarthritis. JAMA. 2001;286(2):188–195.
    1. Felson DT, McLaughlin S, Goggins J, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med. 2003;139(5 Pt 1):330–336.
    1. Taljanovic MS, Graham AR, Benjamin JB, et al. Bone marrow edema pattern in advanced hip osteoarthritis: quantitative assessment with magnetic resonance imaging and correlation with clinical examination, radiographic findings, and histopathology. Skeletal radiology. 2008;37(5):423–431.
    1. Felson DT, Niu J, Neogi T, et al. Synovitis and the risk of knee osteoarthritis: the MOST Study. Osteoarthritis Cartilage. 2016;24:458–464.
    1. Wood MJ, Leckenby A, Reynolds G, et al. Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients. JCI insight 2019;4(2):e125325.
    1. Orlowsky EW, Kraus VB. The Role of Innate Immunity in Osteoarthritis: When Our First Line of Defense Goes On the Offensive. The Journal of rheumatology. 2015; 42(3):363–371.
    1. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51(2):249–257.
    1. Sohn DH, Sokolove J, Sharpe O, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis research & therapy. 2012;14(1):R7–R7.
    1. van den Bosch MHJ, van Lent P, van der Kraan PM. Identifying effector molecules, cells, and cytokines of innate immunity in OA. Osteoarthritis Cartilage. 2020;28(5):532–543.
    1. Lieberthal J, Sambamurthy N, Scanzello CR. Inflammation in joint injury and post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2015;23(11):1825–1834.
    1. Collins JE, Katz JN, Dervan EE, Losina E. Trajectories and risk profiles of pain in persons with radiographic, symptomatic knee osteoarthritis: data from the osteoarthritis initiative. Osteoarthritis Cartilage. 2014;22(5):622–630.
    1. Duncan R, Peat G, Thomas E, Wood L, Hay E, Croft P. Does isolated patellofemoral osteoarthritis matter? Osteoarthritis Cartilage. 2009;17(9):1151–1155.
    1. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039–1049.
    1. Metcalfe D, Perry DC, Claireaux HA, Simel DL, Zogg CK, Costa ML. Does This Patient Have Hip Osteoarthritis?: The Rational Clinical Examination Systematic Review. JAMA. 2019;322(23):2323–2333.
    1. Does This Patient Have Hip Osteoarthritis: How to Provide a Hip Examination for Hip Osteoarthritis [Video]: JAMA Network 2019.
    1. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis & Rheumatism. 1991;34(5):505–514.
    1. Kohn MD, Sassoon AA, Fernando ND. Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis. Clin Orthop Relat Res. 2016;474(8):1886–1893.
    1. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494–502.
    1. Gold GE, Cicuttini F, Crema MD, et al. OARSI Clinical Trials Recommendations: Hip imaging in clinical trials in osteoarthritis. Osteoarthritis Cartilage. 2015;23(5):716–731.
    1. Hunter DJ, Zhang W, Conaghan PG, et al. Systematic review of the concurrent and predictive validity of MRI biomarkers in OA. Osteoarthritis Cartilage. 2011;19(5):557–588.
    1. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet (London, England). 2011;377(9783):2115–2126.
    1. Podlipská J, Guermazi A, Lehenkari P, et al. Comparison of Diagnostic Performance of Semi-Quantitative Knee Ultrasound and Knee Radiography with MRI: Oulu Knee Osteoarthritis Study. Scientific Reports. 2016;6:22365.
    1. Fernandes L, Hagen KB, Bijlsma JW, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis. 2013;72(7):1125–1135.
    1. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000;59(12):936–944.
    1. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–1155.
    1. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669–681.
    1. Jevsevar DS. Treatment of Osteoarthritis of the Knee: Evidence-Based Guideline, 2nd Edition. JAAOS - Journal of the American Academy of Orthopaedic Surgeons. 2013;21(9):571–576.
    1. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology. 2020;72(2):220–233.
    1. Kovar PA, Allegrante JP, MacKenzie CR, Peterson MGE, Gutin B, Charlson ME. Supervised Fitness Walking in Patients with Osteoarthritis of the Knee. Annals of internal medicine. 1992;116(7):529–534.
    1. Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263–1273.
    1. Reichenbach S, Felson DT, Hincapié CA, et al. Effect of Biomechanical Footwear on Knee Pain in People With Knee Osteoarthritis: The BIOTOK Randomized Clinical Trial. JAMA. 2020;323(18):1802–1812.
    1. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. The American journal of gastroenterology. 2009;104(3):728–738.
    1. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Annals of internal medicine. 2015;162(1):46–54.
    1. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004;51(5):746–754.
    1. Leopoldino AO, Machado GC, Ferreira PH, et al. Paracetamol versus placebo for knee and hip osteoarthritis. The Cochrane database of systematic reviews. 2019;2(2):Cd013273.
    1. Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ (Clinical research ed). 2015;350:h1225.
    1. Zhu X, Wu D, Sang L, et al. Comparative effectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/or hip osteoarthritis: a network meta-analysis. Clinical and experimental rheumatology. 2018;36(4):595–602.
    1. Cheng OT, Souzdalnitski D, Vrooman B, Cheng J. Evidence-based knee injections for the management of arthritis. Pain Med. 2012;13(6):740–753.
    1. McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2017;317(19):1967–1975.
    1. Deyle GD, Allen CS, Allison SC, et al. Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee. The New England journal of medicine. 2020;382(15):1420–1429.
    1. Conaghan PG, Hunter DJ, Cohen SB, et al. Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study. J Bone Joint Surg Am. 2018;100(8):666–677.
    1. Zeng C, Lane NE, Hunter DJ, et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthritis Cartilage. 2019;27(6):855–862.
    1. Hochberg MC, Wohlreich M, Gaynor P, Hanna S, Risser R. Clinically Relevant Outcomes Based on Analysis of Pooled Data from 2 Trials of Duloxetine in Patients with Knee Osteoarthritis. The Journal of Rheumatology. 2012;39(2):352.
    1. Osani MC, Bannuru RR. Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis. Korean J Intern Med. 2019;34(5):966–973.
    1. Enteshari-Moghaddam A, Azami A, Isazadehfar K, Mohebbi H, Habibzadeh A, Jahanpanah P. Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis. Clinical rheumatology. 2019;38(10):2873–2880.
    1. Fleischmann RM, Bliddal H, Blanco FJ, et al. A Phase 2 Trial of Lutikizumab, an Anti-Interleukin 1alpha/beta Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis & rheumatology. 2019;71:1056–1069.
    1. Kloppenburg M, Peterfy C, Haugen IK, et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1alpha and anti-interleukin-1beta dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis. 2019;78:413–420.
    1. Kloppenburg M, Ramonda R, Bobacz K, et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(12):1757–1764.
    1. Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement. Annals of internal medicine. 0(0):null.
    1. Yazici Y, McAlindon TE, Fleischmann R, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage. 2017;25(10):1598–1606.
    1. Hochberg MC, Guermazi A, Guehring H, et al. Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial. JAMA. 2019;322(14):1360–1370.
    1. Conaghan PG, Bowes MA, Kingsbury SR, et al. Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized, Placebo-Controlled Trial. Annals of internal medicine. 202-;172(2):86–95.
    1. Quality AfHRa. Healthcare Cost and Utilization Project 2014.
    1. Katz JN, Losina E, Barrett J, et al. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States medicare population. J Bone Joint Surg Am. 2001;83(11):1622–1629.
    1. Memtsoudis SG, Della Valle AG, Besculides MC, Esposito M, Koulouvaris P, Salvati EA. Risk factors for perioperative mortality after lower extremity arthroplasty: a population-based study of 6,901,324 patient discharges. The Journal of arthroplasty. 2010;25(1):19–26.
    1. Mahomed NN, Barrett J, Katz JN, Baron JA, Wright J, Losina E. Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am. 2005;87(6):1222–1228.
    1. Inacio MCS, Dillon MT, Miric A, Navarro RA, Paxton EW. Mortality After Total Knee and Total Hip Arthroplasty in a Large Integrated Health Care System. Perm J. 2017;21:16–171.
    1. Beswick AD, Wylde V, Gooberman-Hill R, Blom A, Dieppe P. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. BMJ Open. 2012;2(1):e000435.
    1. Skou ST, Roos EM, Laursen MB, et al. A Randomized, Controlled Trial of Total Knee Replacement. New England Journal of Medicine. 2015;373(17):1597–1606.
    1. Evans JT, Walker RW, Evans JP, Blom AW, Sayers A, Whitehouse MR. How long does a knee replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up. The Lancet. 2019;393(10172):655–663.
    1. Evans JT, Evans JP, Walker RW, Blom AW, Whitehouse MR, Sayers A. How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up. Lancet (London, England). 2019;393(10172):647–654.
    1. Jasper LL, Jones CA, Mollins J, Pohar SL, Beaupre LA. Risk factors for revision of total knee arthroplasty: a scoping review. BMC musculoskeletal disorders. 2016;17:182–182.
    1. Prokopetz JJ, Losina E, Bliss RL, Wright J, Baron JA, Katz JN. Risk factors for revision of primary total hip arthroplasty: a systematic review. BMC musculoskeletal disorders. 2012;13:251–251.
    1. Katz JN, Wright EA, Wright J, et al. Twelve-year risk of revision after primary total hip replacement in the U.S. Medicare population. J Bone Joint Surg Am. 2012;94(20):1825–1832.
    1. Moseley JB, O’Malley K, Petersen NJ, et al. A Controlled Trial of Arthroscopic Surgery for Osteoarthritis of the Knee. New England Journal of Medicine. 2002;347(2):81–88.
    1. Katz JN, Wright J, Spindler KP, et al. Predictors and Outcomes of Crossover to Surgery from Physical Therapy for Meniscal Tear and Osteoarthritis: A Randomized Trial Comparing Physical Therapy and Surgery. J Bone Joint Surg Am. 2016;98(22):1890–1896.
    1. Katz JN, Brophy RH, Chaisson CE, et al. Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis. New England Journal of Medicine. 2013;368(18):1675–1684.
    1. Zhang W, Lyman S, Boutin-Foster C, et al. Racial and Ethnic Disparities in Utilization Rate, Hospital Volume, and Perioperative Outcomes After Total Knee Arthroplasty. J Bone Joint Surg Am. 2016;98(15):1243–1252.
    1. Cavanaugh AM, Rauh MJ, Thompson CA, et al. Racial and ethnic disparities in utilization of total knee arthroplasty among older women. Osteoarthritis Cartilage. 2019;27(12):1746–1754.
    1. Mahomed NN, Barrett JA, Katz JN, et al. Rates and Outcomes of Primary and Revision Total Hip Replacement in the United States Medicare Population. JBJS. 2003;85(1).
    1. Hausmann LRM, Mor M, Hanusa BH, et al. The effect of patient race on total joint replacement recommendations and utilization in the orthopedic setting. J Gen Intern Med. 2010;25(9):982–988.
    1. Byrne MM, Souchek J, Richardson M, Suarez-Almazor M. Racial/ethnic differences in preferences for total knee replacement surgery. Journal of clinical epidemiology. 2006;59(10):1078–1086.
    1. Ibrahim SA, Siminoff LA, Burant CJ, Kwoh CK. Understanding ethnic differences in the utilization of joint replacement for osteoarthritis: the role of patient-level factors. Medical care. 2002;40(1 Suppl):I44–51.
    1. Nwachukwu BU, Kenny AD, Losina E, Chibnik LB, Katz JN. Complications for Racial and Ethnic Minority Groups After Total Hip and Knee Replacement: A Review of the Literature. JBJS. 2010;92(2).
    1. Deveza LA, Nelson AE, Loeser RF. Phenotypes of osteoarthritis: current state and future implications. Clinical and experimental rheumatology. 2019;37 Suppl 120(5):64–72.
    1. Nelson AE, Fang F, Arbeeva L, et al. A machine learning approach to knee osteoarthritis phenotyping: data from the FNIH Biomarkers Consortium. Osteoarthritis Cartilage. 2019;27(7):994–1001.
    1. Huang Z, Ding C, Li T, Yu SP. Current status and future prospects for disease modification in osteoarthritis. Rheumatology (Oxford). 2017;57(suppl 4):iv108–iv123.
    1. Jeon OH, Kim C, Laberge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017;23(6):775–781.
    1. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. The New England journal of medicine. 2010;363(16):1521–1531.
    1. Sanga P, Katz N, Polverejan E, et al. Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study. Arthritis & rheumatology. 2017;69(4):763–773.
    1. Schnitzer TJ, Easton R, Pang S, et al. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. JAMA : the journal of the American Medical Association. 2019;322(1):37–48.
    1. Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23 Suppl 1:S18–21.
    1. Chapple CM, Nicholson H, Baxter GD, Abbott JH. Patient characteristics that predict progression of knee osteoarthritis: a systematic review of prognostic studies. Arthritis Care Res (Hoboken). 2011;63(8):1115–1125.
    1. Bastick AN, Runhaar J, Belo JN, Bierma-Zeinstra SMA. Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies. Arthritis Research & Therapy. 2015;17(1):152.
    1. Treatment of Osteoarthritis of the Knee: Evidence-Based Guideline. In: Surgeons AAoO, ed. 2nd ed 2013.
    1. Fernandes L, Hagen KB, Bijlsma JW, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis. 2013;72(7):1125–1135.

Source: PubMed

3
購読する